JP7871988B2 - Nrp1結合ドメインを含む二重特異性抗体およびその使用方法 - Google Patents

Nrp1結合ドメインを含む二重特異性抗体およびその使用方法

Info

Publication number
JP7871988B2
JP7871988B2 JP2024557935A JP2024557935A JP7871988B2 JP 7871988 B2 JP7871988 B2 JP 7871988B2 JP 2024557935 A JP2024557935 A JP 2024557935A JP 2024557935 A JP2024557935 A JP 2024557935A JP 7871988 B2 JP7871988 B2 JP 7871988B2
Authority
JP
Japan
Prior art keywords
seq
domain
binding
sequence shown
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024557935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511135A5 (cg-RX-API-DMAC7.html
JP2025511135A (ja
Inventor
ソン,ホジュン
チェ,ソンヒュ
ジョン ロソマンド,アンソニー
ラインシャーゲン,クレメンス
チョン,ウィジュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pinetree Therapeutics Inc
Original Assignee
Pinetree Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinetree Therapeutics Inc filed Critical Pinetree Therapeutics Inc
Publication of JP2025511135A publication Critical patent/JP2025511135A/ja
Publication of JP2025511135A5 publication Critical patent/JP2025511135A5/ja
Application granted granted Critical
Publication of JP7871988B2 publication Critical patent/JP7871988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024557935A 2022-03-30 2023-03-30 Nrp1結合ドメインを含む二重特異性抗体およびその使用方法 Active JP7871988B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263325312P 2022-03-30 2022-03-30
US202263325317P 2022-03-30 2022-03-30
US63/325,312 2022-03-30
US63/325,317 2022-03-30
PCT/US2023/016963 WO2023192514A1 (en) 2022-03-30 2023-03-30 Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026080898A Division JP2026133506A (ja) 2022-03-30 2026-05-13 Nrp1結合ドメインを含む二重特異性抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2025511135A JP2025511135A (ja) 2025-04-15
JP2025511135A5 JP2025511135A5 (cg-RX-API-DMAC7.html) 2025-11-04
JP7871988B2 true JP7871988B2 (ja) 2026-06-09

Family

ID=86184900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557935A Active JP7871988B2 (ja) 2022-03-30 2023-03-30 Nrp1結合ドメインを含む二重特異性抗体およびその使用方法

Country Status (13)

Country Link
US (1) US12692315B2 (cg-RX-API-DMAC7.html)
EP (1) EP4499696A1 (cg-RX-API-DMAC7.html)
JP (1) JP7871988B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240163751A (cg-RX-API-DMAC7.html)
CN (1) CN119403831A (cg-RX-API-DMAC7.html)
AU (1) AU2023245728A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255754A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002899A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024014799A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240462A (cg-RX-API-DMAC7.html)
IL (1) IL315960A (cg-RX-API-DMAC7.html)
MX (1) MX2024011978A (cg-RX-API-DMAC7.html)
WO (1) WO2023192514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315960A (en) 2022-03-30 2024-11-01 Pinetree Therapeutics Inc Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
AU2023317484A1 (en) * 2022-07-30 2025-03-13 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof
IL320410A (en) * 2022-11-07 2025-06-01 Pinetree Therapeutics Inc Combination therapy involving bispecific antibodies containing an NRP1 binding domain

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514972A (ja) 2005-11-08 2009-04-09 ジェネンテック・インコーポレーテッド ニューロピリンアンタゴニスト
US20190062375A1 (en) 2016-03-29 2019-02-28 Ajou University Industry-Academic Cooperation Foun Dation Composition for overcoming resistance to egfr-targeting agent
WO2020027224A1 (ja) 2018-07-31 2020-02-06 国立大学法人東京大学 新たな結合特異性を抗体に付与する超汎用法
WO2020079280A1 (en) 2018-10-19 2020-04-23 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of squamous cell cancers
JP2020517659A (ja) 2017-04-24 2020-06-18 イクノス サイエンシズ エスエー Egfr陽性癌の治療のためのt細胞リダイレクト二重特異性抗体

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6302874B1 (en) 1998-07-13 2001-10-16 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗her2抗体改変体
ME01803B (me) 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
GB0503546D0 (en) 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
CA2628253A1 (en) 2005-11-03 2007-08-30 Genentech, Inc. Therapeutic anti-her2 antibody fusion polypeptides
US20100143340A1 (en) 2006-12-13 2010-06-10 Schering Corporation Methods and compositions for treating cancer
PL2155788T3 (pl) * 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
US20140112911A9 (en) 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody
WO2010099186A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Her2 antibody compositions
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
WO2011057064A1 (en) 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
WO2011143408A1 (en) 2010-05-13 2011-11-17 Genentech, Inc. Use of neuropilin-1 antagonists for the treatment of cancer
JP5908972B2 (ja) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
AU2012255920A1 (en) 2011-05-18 2013-11-07 Merck Sharp & Dohme Corp. Therapeutic anti-IGF1R combinations
CN102492039B (zh) 2011-11-21 2015-03-11 无锡天演生物技术有限公司 全人源抗人her2单抗
EP2863947B1 (en) 2012-06-21 2018-03-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind igf1r
WO2014189303A1 (ko) 2013-05-23 2014-11-27 아주대학교산학협력단 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질
JP6541237B2 (ja) 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子1受容体特異的抗体及びそれらの使用
EP3114142B1 (en) 2014-03-06 2019-06-05 National Research Council of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
US9975960B2 (en) 2014-05-09 2018-05-22 Samsung Electronics Co., Ltd. Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
KR101551306B1 (ko) 2015-03-23 2015-09-09 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도
ES3043088T3 (en) 2015-06-17 2025-11-24 Hoffmann La Roche Anti-her2 antibodies and methods of use
WO2017171373A2 (ko) * 2016-03-29 2017-10-05 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
KR101985299B1 (ko) 2016-06-03 2019-09-03 삼성전자주식회사 항-c-Met/항-Nrp1 이중 특이 항체
US10167342B2 (en) 2016-08-29 2019-01-01 Fazel Shokri Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment
LT3512882T (lt) 2016-09-14 2021-06-25 Merck Patent Gmbh Anti-c-met antikūnai ir jų antikūno-vaisto konjugatai, skirti efektyviam naviko slopinimui
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
EP3680250A4 (en) 2017-09-08 2021-07-14 Ajou University Industry-Academic Cooperation Foundation COMPOSITION LIMITING THE ACTIVITY OF A REGULATING T LYMPHOCYTE, INCLUDING A PEPTIDIC BINDING SPECIFIC TO NEUROPILIN 1 (NRP1)
KR102054389B1 (ko) 2017-10-26 2019-12-11 아주대학교산학협력단 뉴로필린1에 특이적으로 결합하는 Non-CendR 펩타이드, 상기 펩타이드가 융합된 융합 단백질 및 이의 용도
JP2022510218A (ja) 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
MX2021008121A (es) 2019-01-03 2021-12-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer.
WO2022026943A2 (en) 2020-07-31 2022-02-03 Pinetree Therapeutics, Inc. Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections
IL315960A (en) 2022-03-30 2024-11-01 Pinetree Therapeutics Inc Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
IL320410A (en) 2022-11-07 2025-06-01 Pinetree Therapeutics Inc Combination therapy involving bispecific antibodies containing an NRP1 binding domain
EP4754135A1 (en) 2023-07-28 2026-06-10 Pinetree Therapeutics, Inc. Non-receptor tyrosine kinase compositions for targeted lysosomal degradation and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514972A (ja) 2005-11-08 2009-04-09 ジェネンテック・インコーポレーテッド ニューロピリンアンタゴニスト
US20190062375A1 (en) 2016-03-29 2019-02-28 Ajou University Industry-Academic Cooperation Foun Dation Composition for overcoming resistance to egfr-targeting agent
JP2020517659A (ja) 2017-04-24 2020-06-18 イクノス サイエンシズ エスエー Egfr陽性癌の治療のためのt細胞リダイレクト二重特異性抗体
WO2020027224A1 (ja) 2018-07-31 2020-02-06 国立大学法人東京大学 新たな結合特異性を抗体に付与する超汎用法
WO2020079280A1 (en) 2018-10-19 2020-04-23 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of squamous cell cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Letters,2019年,vol.466,p.23-34

Also Published As

Publication number Publication date
CR20240462A (es) 2024-12-11
AU2023245728A1 (en) 2024-09-26
JP2025511135A (ja) 2025-04-15
CA3255754A1 (en) 2023-10-05
KR20240163751A (ko) 2024-11-19
US12692315B2 (en) 2026-07-28
CL2024002899A1 (es) 2025-02-07
EP4499696A1 (en) 2025-02-05
CO2024014799A2 (es) 2024-11-18
CN119403831A (zh) 2025-02-07
IL315960A (en) 2024-11-01
MX2024011978A (es) 2025-02-10
WO2023192514A1 (en) 2023-10-05
US20240101682A1 (en) 2024-03-28

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251023

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260507

R150 Certificate of patent or registration of utility model

Ref document number: 7871988

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150